Spectral Medical Announces Appointment of Leading Industry Executive Sam Amory as Dialco President
16 Mai 2022 - 01:30PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT), a late-stage theranostic company advancing
therapeutic options for sepsis and septic shock, as well as
commercializing a new proprietary platform targeting the renal
replacement therapy market through its wholly-owned subsidiary
Dialco Medical Inc. (“Dialco”), today announced the appointment of
Samuel Amory as President of Dialco.
Mr. Amory brings decades of experience in the
medical device and dialysis fields. Since 2005, he served as Vice
President of the US Renal Therapies division at B. Braun Medical, a
leader in fluid therapy and pain management. During his tenure, he
was responsible for driving strategy development and implementation
of all aspects of the dialysis business, including sales,
marketing, technical operations, and new product development for a
diverse and complex product line. Mr. Amory managed a large team of
professionals within sales, technical support, marketing, and
customer service. During his tenure, he launched a start-up
division that grew to the number two position in the U.S. market.
Mr. Amory was also involved in significant acquisitions, contract
negotiations and expansion of the product portfolio. Previously, he
served as Director/Manager of sales at B. Braun Medical, where he
transformed the division from a distribution to direct sales model,
resulting in significant revenue growth. Mr. Amory has a Bachelor
of Science in Chemical Engineering from Pennsylvania State
University.
Chris Seto, CEO of Spectral, commented, “Sam is
an important and timely addition to our senior management team, as
we accelerate the roll out of our SAMI device and advance the DIMI
usability trial to obtain FDA clearance for in-home use. He brings
an impressive track record, including new product launches,
building sales organizations, and M&A, with deep expertise in
the field of dialysis. We look forward to his contributions as we
work towards our goal of establishing Dialco as a leader in both
the acute and chronic care renal replacement therapy markets.”
Mr. Amory further noted, “I am excited to join
Dialco at this exciting time in it’s development. The SAMI device
is remarkable in its simplicity and usability, which makes it ideal
for adoption within the acute care setting. The DIMI device, built
on the same platform, addresses key barriers to adoption of home
hemodialysis, while providing a better patient experience and
lowering overall healthcare costs. I look forward to leveraging my
background and industry relationships to help maximize the
commercial potential of these first-in-class devices.”
About Spectral
Spectral is a Phase 3 company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX is approved for therapeutic use in Japan and
Europe, and has been used safely and effectively on more than
340,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. Approximately 330,000 patients are
diagnosed with severe sepsis and septic shock in North America each
year.
Spectral, through its wholly owned subsidiary,
Dialco Medical Inc., is also commercializing a new set of
proprietary platforms addressing renal replacement therapy (RRT)
across the dialysis spectrum. SAMI is targeting the acute RRT
market, while DIMI is targeting the chronic RRT market. Dialco is
currently pursuing regulatory approval for U.S. in-home use of
DIMI, which is based on the same RRT platform as SAMI, but will be
intended for home hemodialysis use. DIMI recently received its FDA
510k clearance for use in hospital and clinical settings, and
obtained its Health Canada license for use within Canadian
hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information, please visit
www.spectraldx.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ
materially from what is currently expected.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Contact:
Mr. Blair McInnis |
Mr. Ali Mahdavi |
David Waldman/Natalya Rudman |
CFO |
Capital Markets & Investor
Relations |
US Investor Relations |
Spectral Medical Inc. |
Spinnaker Capital Markets
Inc. |
Crescendo Communications,
LLC |
416-626-3233 |
416-962-3300 |
212-671-1020 |
bmcinnis@spectraldx.com |
am@spinnakercmi.com |
edt@crescendo-ir.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mär 2023 bis Mär 2024